Background: Antiphospholipid antibodies (aPL) trigger inflammation, vasculopathy, and thrombosis, sharing pathophysiological mechanisms with atherosclerosis. However, their association with incident ...

Alirocumab is a fully human monoclonal antibody to PCSK9. The ODYSSEY MONO study was the first alirocumab Phase III study to test a previously unused dose of 75 mg subcutaneously every 2 weeks in ...

The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...

Inclisiran was used in 3 studies, evolocumab in 5, alirocumab in 2, and tafolecimab in 1 ... No significant difference in binding antibodies was observed (RR: 2.50, 95% CI: 0.13-49.47, P = 0.55; I^2 = ...

These are important data and provide further data regarding the utility of PCSK9 monoclonal antibodies for secondary prevention in high-risk patients (such as those with AMI) as combination therapy ...

State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China ...

The mixed results are a blow for bepranemab and for related antibodies that target a mid-region epitope on tau. But exploratory analyses of the results hint at a path forward for these candidates.

The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development. The company was spun ...

Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 465-8603, Japan Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural ...